No, that would need to be disclosed to the market. As OPT302 is their only drug candidate any contract regarding it would be material, thus disclosed. More likely, a few drug companies will make offers as soon as they see the results of the DME study.Yes, afaik, they are required under the listing rules to put out a 4C due to how small they are and that they lack any revenues.
Edit to add: I doubt the 4C will tell us anything at the moment that hasn't already been said by the company or to shareholders.
Yes, afaik, they are required under the listing rules to put out...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.8¢ |
Change
0.028(6.71%) |
Mkt cap ! $535.5M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 44.0¢ | 42.0¢ | $2.578M | 5.926M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 15141 | 43.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.0¢ | 62395 | 8 |
View Market Depth
| Last trade - 15.39pm 29/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |